FDA Clears Initiation of COVID-19 Adaptive Platform Trial Developed by ACESO
Initiation of ACESO's COVID-19 adaptive platform trial (PROTECT-APT) received FDA approval. FHI Clinical is the CRO and IND sponsor across sites internationally
Contract research organizations gain competitive edge with Oracle Cloud
February 2, 2023
Oracle is supporting CROs with no-obligation access to its Clinical One platform through its CRO Growth Initiative. Read why we chose the platform as our default eClinical system.
Latest findings from a PREVAIL partnership contribute to the prevention of Ebola virus disease
January 30, 2023 Members of the PREVAIL team, with their research partners, recently published results from clinical trials of three vaccine regimens against Zaire Ebola virus disease (EVD).
FHI Clinical collaborating with Tactical Therapeutics, Inc., to refine the protocol for the development of carboxyamidotriazole orotate (CTO) to treat respiratory diseases
December 21, 2022 FHI Clinical is contributing to the protocol design for a Phase 2 clinical trial to evaluate carboxyamidotriazole orotate (CTO), an asset from Tactical Therapeutics.
Partner with FHI Clinical to confidently conduct high-quality research in sub-Saharan Africa
October 12, 2022 FHI Clinical Inc. is showcasing sub-Saharan Africa as a clinical trial destination through its 8-week FHI Clinical Africa campaign, culminating in a celebration at World Vaccine Congress Europe of the region’s rich cultural heritage and growing target as a hub for global clinical trials.
Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study
September 7, 2022 The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.
FHI Clinical to write clinical trial protocol for development of Gb Sciences’ COVID-19-related anti-inflammatory therapies
May 2, 2022 FHI Clinical Inc. announces today it will consult on the go-to-market strategy for COVID-19 related anti-inflammatory therapeutics for Gb Sciences. FHI Clinical will additionally write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.
FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)
February 8, 2022 FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.
FHI Clinical announces intent to acquire South African-based Triclinium Clinical Development (TCD)
December 2, 2021 FHI Clinical announces its intent to acquire TCD Global, a South African-based CRO. The acquisition allows FHI Clinical to expand its share of the infectious disease (ID) clinical development market and become the dominant service provider in sub-Saharan Africa.
Evaluation of early warning systems for clinical assessment of patients with COVID-19 in the global study, ACTT-1
September 21, 2021 The results from this study provide important information about the clinical management of hospitalized patients with COVID-19. Additional research is needed to identify a method that can be used to accurately prioritize patients with COVID-19 at risk of critical illness or death.
